Country: Канада
Језик: Енглески
Извор: Health Canada
NICOTINIC ACID; LOVASTATIN
SEPRACOR PHARMACEUTICALS INC
C10BA01
LOVASTATIN AND NICOTINIC ACID
1000MG; 20MG
TABLET (IMMEDIATE RELEASE)
NICOTINIC ACID 1000MG; LOVASTATIN 20MG
ORAL
90
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0251302002; AHFS:
CANCELLED POST MARKET
2012-08-02
PRODUCT MONOGRAPH PR ADVICOR ® extended-release niacin and lovastatin tablets 500/20 mg, 750/20 mg, 1000/20 mg and 1000/40 mg Film-Coated Tablets Lipid Metabolism Regulator Manufacturer: DATE OF REVISION : Sepracor Pharmaceuticals, Inc. OCTOBER 29, 2010 Mississauga, Ontario Canada CONTROL NO. 141231 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION........................................................ 3 SUMMARY PRODUCT INFORMATION................................................................................ 3 INDICATIONS AND CLINICAL USE...................................................................................... 3 CONTRAINDICATIONS........................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 10 DRUG INTERACTIONS.......................................................................................................... 16 DOSAGE AND ADMINISTRATION...................................................................................... 17 OVERDOSAGE ........................................................................................................................ 19 ACTION AND CLINICAL PHARMACOLOGY.................................................................... 19 STORAGE AND STABILITY ................................................................................................. 23 DOSAGE FORMS, COMPOSITION AND PACKAGING..................................................... 23 PART II: SCIENTIFIC INFORMATION .............................................................................. 24 PHARMACEUTICAL INFORMATION ................................................................................. 24 CLINICAL TRIALS........................................................................................... Прочитајте комплетан документ